Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Personalizing chemotherapy drug selection using a novel transcriptomic chemogram. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical trial design in the era of precision medicine
10.1186/s13073-022-01102-1 · 2022 · External reference
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients 2006 -2020
10.1016/j.annonc.2021.04.003 · 2021 · External reference
Drug independence and the curability of cancer by combination chemotherapy
10.1016/j.trecan.2022.06.009 · 2022 · External reference
Hospital antibiogram: a necessity
10.4103/0255-0857.71802 · 2010 · External reference
Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response
10.1038/s41698-018-0060-3 · 2018 · External reference
Establishment of patient-derived cancer organoids for drug-screening applications
10.1038/s41596-020-0379-4 · 2020 · External reference
Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures
10.1186/s13073-021-01000-y · 2021 · External reference
Gene expression based inference of cancer drug sensitivity
10.1038/s41467-022-33291-z · 2022 · External reference
A deep learning framework for predicting response to therapy in cancer
10.1016/j.celrep.2019.11.017 · 2019 · External reference
Evolution-informed strategies for combating drug resistance in cancer
10.3390/ijms24076738 · 2023 · External reference
Prospective validation of a genomic assay in breast cancer: the 70-gene mammaprint assay and the MINDACT trial
10.5644/ama2006-124.239 · 2019 · External reference
The era of multigene panels comes? The clinical utility of oncotype DX and MammaPrint
10.14740/wjon1019w · 2017 · External reference
Spotlight on the utility of the oncotype DX® breast cancer assay
10.2147/ijwh.s124520 · 2018 · External reference
10.1200/jco.2013.31.15_suppl.5005
10.1200/jco.2013.31.15_suppl.5005 · External reference
Prolaris test for prostate cancer risk assessment
2019 · External reference
A 22 gene-expression assay, Decipher® (GenomeDx Biosciences) to predict five-year risk of metastatic prostate cancer in men treated with radical prostatectomy
2015 · External reference
Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature
10.1038/s41698-023-00375-y · 2023 · External reference
Current therapeutic approaches in metastatic and recurrent ewing sarcoma
10.1155/2011/863210 · 2011 · External reference
Current and future treatment strategies for rhabdomyosarcoma
10.3389/fonc.2019.01458 · 2019 · External reference
Unresolved reference
External reference
limma powers differential expression analyses for RNA-sequencing and microarray studies
10.1093/nar/gkv007 · 2015 · External reference
oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data
10.1093/bib/bbab260 · 2021 · External reference
Differential expression in RNA-seq: a matter of depth
10.1101/gr.124321.111 · 2011 · External reference
Gene expression hallmarks of cellular ageing
10.1007/s10522-018-9750-z · 2018 · External reference
Independent drug action and its statistical implications for development of combination therapies
10.1016/j.cct.2020.106126 · 2020 · External reference
Additivity predicts the efficacy of most approved combination therapies for advanced cancer
10.1038/s43018-023-00667-z · 2023 · External reference
Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy
10.1016/j.cell.2017.11.009 · 2017 · External reference
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
10.1038/s41467-020-16212-w · 2020 · External reference
Local cancer recurrence: the realities, challenges, and opportunities for new therapies
2018 · External reference
Optimal therapy scheduling based on a pair of collaterally sensitive drugs
10.1007/s11538-018-0434-2 · 2018 · External reference
Theoretical modeling of collaterally sensitive drug cycles: shaping heterogeneity to allow adaptive therapy
10.1007/s00285-021-01671-6 · 2021 · External reference
Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance
10.1371/journal.pbio.3000515 · 2019 · External reference
10.1101/2023.01.12.523765
10.1101/2023.01.12.523765 · External reference
Understanding resistance to combination chemotherapy
10.1016/j.drup.2012.10.003 · 2012 · External reference
The Toxicity Of Poisons Applied Jointly1
10.1111/j.1744-7348.1939.tb06990.x · 1939 · External reference
The problem of synergism and antagonism of combined drugs
1953 · External reference
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism
10.1158/1535-7163.mct-23-0642 · 2024 · External reference
Optimizing adaptive cancer therapy: dynamic programming and evolutionary game theory
2020 · External reference
Stratification and prediction of drug synergy based on target functional similarity
10.1038/s41540-020-0136-x · 2020 · External reference
Advances in computational approaches in identifying synergistic drug combinations
2018 · External reference
Recent advances in combinatorial drug screening and synergy scoring
10.1016/j.coph.2018.07.008 · 2018 · External reference
Analysis of racial/ethnic representation in select basic and applied cancer research studies
10.1038/s41598-018-32264-x · 2018 · External reference
Population-based differences in treatment outcome following anticancer drug therapies
10.1016/s1470-2045(09)70160-3 · 2010 · External reference
The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology
10.3349/ymj.2013.54.1.1 · 2013 · External reference
Cancer pharmacogenomics: implications on ethnic diversity and drug response
10.1097/fpc.0000000000000134 · 2015 · External reference
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy
10.1158/1078-0432.ccr-09-0344 · 2009 · External reference
Unresolved reference
External reference
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
2013 · External reference
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
10.1093/biostatistics/4.2.249 · 2003 · External reference
A landscape of pharmacogenomic interactions in cancer
10.1016/j.cell.2016.06.017 · 2016 · External reference
RTCGAToolbox: a new tool for exporting TCGA Firehose data
10.1371/journal.pone.0106397 · 2014 · External reference
10.1073/pnas.091062498
10.1073/pnas.091062498 · External reference
10.1007/0-387-29362-0_15
10.1007/0-387-29362-0_15 · External reference
